Clinical Trials Sponsored by Novo Nordisk A/S

Total 1549 results

Novo Nordisk A/S

Completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Netherlands
Novo Nordisk A/S

Completed

O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait (O-SEMA-Fast)

Diabetes Mellitus, Type 2

United Arab Emirates, Kuwait, Saudi Arabia
Novo Nordisk A/S

Completed

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Sweden
Novo Nordisk A/S

Completed

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Hungary, Greece
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® (pathfinder9)

Haemophilia A

Austria, Spain, Bulgaria, Croatia, Estonia, Hungary, Italy, Lithuania, Portugal, Greece, Germany, Czechia, Slovenia, Switzerland, Slovakia
Novo Nordisk A/S

Completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men

Diabetes Mellitus, Type 2

China
Novo Nordisk A/S

Completed

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

Obesity

United States
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Non-alcoholic Steatohepatitis (NASH)

Germany
Novo Nordisk A/S

Completed

A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Enrolling by invitation

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

Obesity | Overweight | Pregnancy

United States
Novo Nordisk A/S

Completed

Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes (STEP 10)

Obesity

United Kingdom, Canada, Denmark, Finland, Spain
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) (ONWARDS 3)

Diabetes Mellitus, Type 2

United States, Mexico, Puerto Rico, Canada, Denmark, France, Austria, Taiwan, Czechia, Brazil, China, Argentina
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity

Overweight and Obesity

China
Novo Nordisk A/S

Completed

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes (DIABESITY)

Diabetes Mellitus, Type 2 | Diabetes

India
Novo Nordisk A/S

Completed

The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins

Diabetes | Diabetes Mellitus, Type 1

Germany, United Kingdom
Novo Nordisk A/S

Completed

Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide (REPAMET 2)

Diabetes Mellitus, Type 2 | Diabetes

Belgium
Novo Nordisk A/S

Completed

A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People

Healthy Volunteers - Haemophilia A

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

Obesity

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men

Non-alcoholic Fatty Liver Disease

China
Novo Nordisk A/S

Completed

A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump

Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey (BARRIERS-MASLD)

Non-alcoholic Steatohepatitis (MASH) | Non-alcoholic Fatty Liver Disease (MASLD)

India
Novo Nordisk A/S

Enrolling by invitation

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

Obesity | Overweight | Pregnancy

United States, United Kingdom, Spain
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) (ONWARDS 6)

Diabetes Mellitus, Type 1

United States, India, Italy, Russian Federation, United Kingdom, Canada, Netherlands, Austria, Japan, Spain, Germany, Turkey
Novo Nordisk A/S

Completed

A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes (PIONEER 11)

Diabetes Mellitus, Type 2

Taiwan, Serbia, Algeria, Hungary, China, Ukraine
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (STEP-HFpEF)

Obesity

United States, Israel, United Kingdom, Denmark, Germany, Netherlands, Canada, Argentina, Czechia, Hungary, Poland, Spain, Australia
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 5)

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
Novo Nordisk A/S

Completed

Efficacy Study of IL-21 to Treat Metastatic Melanoma

Cancer | Malignant Melanoma

Australia
Novo Nordisk A/S

Completed

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition (RESCUE)

Inflammation | Chronic Kidney Diseases

United States
Novo Nordisk A/S

Enrolling by invitation

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

Haemophilia B

Japan, Denmark
Novo Nordisk A/S

Completed

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Obesity | Overweight

United States, United Kingdom, Canada, Denmark, Finland, Serbia, Poland, Japan, South Africa, Ireland
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

Healthy Volunteers; High Cholesterol

United States
Novo Nordisk A/S

Completed

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity (STEP 7)

Obesity | Diabetes Mellitus, Type 2 | Overweight

Korea, Republic of, Hong Kong, Brazil, China
Novo Nordisk A/S

Completed

An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes (EU-CAPTURE)

Diabetes Mellitus, Type 2

Italy, France, Czechia
Novo Nordisk A/S

Completed

Awareness, Care & Treatment In Obesity Management (ACTION-France)

Obesity

France
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

Type 2 Diabetes | Healthy Volunteers | High Blood Cholesterol Levels

Germany, Canada
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity (STEP 8)

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin (ONWARDS 2)

Diabetes Mellitus, Type 2

Poland, United States, Japan, Korea, Republic of, Germany, Bulgaria, South Africa, Portugal, Ukraine
Novo Nordisk A/S

Completed

Attitudes and Unmet Needs Among Type 2 Diabetes Patients

Type 2 Diabetes

Korea, Republic of, Mexico, India, United Kingdom, Australia, France, Saudi Arabia
Novo Nordisk A/S

Completed

Awareness, Care & Treatment In Obesity Management - An Observation in Mainland China (ACTION China)

Obesity

China
Novo Nordisk A/S

Withdrawn

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records (INSPIRE Turkey)

Obesity

Turkey
Novo Nordisk A/S

Completed

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (pathfinder8)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Croatia, Germany, Brazil, France, Japan, Australia, Hungary, Israel, Korea, Republic of, Lithuania, Portugal, Ukraine, Greece, Italy, Denmark, Norway, Canada and more
Novo Nordisk A/S

Completed

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Obesity or Overweight

Denmark
Novo Nordisk A/S

Completed

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Obesity | Diabetes Mellitus, Type 2 | Overweight | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Withdrawn

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia (GLIDE)

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Withdrawn

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Effect of Fiasp® in Type 1 Diabetes Treatment

Diabetes Mellitus, Type 1

Sweden

3

Subscribe